An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma

Trial Profile

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Prednisolone (Primary) ; Tazemetostat (Primary) ; Midazolam
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Eisai Co Ltd; Epizyme
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Jun 2018 According to an Epizyme media release, the company will conduct an Investor conference call to discuss interim clinical activity and tolerability data from the study.
    • 15 Jun 2018 According to an Epizyme media release, interim data from Phase II portion presented at the 23rd Congress of the European Hematology Association (EHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top